State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Bioactive Natural Product Research, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, PR China.
State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Bioactive Natural Product Research, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, PR China.
Bioorg Chem. 2021 Mar;108:104666. doi: 10.1016/j.bioorg.2021.104666. Epub 2021 Jan 28.
Lysine-specific histone demethylase 1 (LSD1) was the first histone demethylase identified in epigenetics and has recently emerged as an attractive therapeutic target for treating tumors. To date, almost all reported LSD1 inhibitors have been chemosynthesized; however, natural products possess pharmacological and biological activity and can be sources for drug development. Here, we established a target separation countercurrent chromatography technique to isolate LSD1 inhibitors from zedoary turmeric oil. Four sesquiterpene-based LSD1 inhibitors were efficiently obtained with an inhibition ratio equal to or less than that of the positive control drug. Compound 2 showed the most potent inhibitory activity, with a half-maximal inhibitory concentration of 3.97 μM, and was further tested to determine its ability to inhibit LSD1 and its antitumor metastatic effects in MDA-MB-231 cells. These four compounds are the first sesquiterpene-based natural LSD1 inhibitors to be characterized. Our findings provide a new molecular framework for studying LSD1 inhibitors and offer a template for designing more sesquiterpene-based LSD1 inhibitors with potential antitumor activity.
赖氨酸特异性组蛋白去甲基化酶 1(LSD1)是在表观遗传学中鉴定的第一个组蛋白去甲基化酶,最近已成为治疗肿瘤的有吸引力的治疗靶点。迄今为止,几乎所有报道的 LSD1 抑制剂都是化学合成的;然而,天然产物具有药理学和生物学活性,并且可以作为药物开发的来源。在这里,我们建立了一种靶分离逆流色谱技术,从莪术油中分离 LSD1 抑制剂。用与阳性对照药物相等或更低的抑制率有效地获得了四种基于倍半萜的 LSD1 抑制剂。化合物 2 显示出最强的抑制活性,半最大抑制浓度为 3.97 μM,并且进一步测试了其抑制 LSD1 的能力及其在 MDA-MB-231 细胞中的抗肿瘤转移作用。这四种化合物是首次鉴定的基于倍半萜的天然 LSD1 抑制剂。我们的研究结果为研究 LSD1 抑制剂提供了新的分子框架,并为设计具有潜在抗肿瘤活性的更多基于倍半萜的 LSD1 抑制剂提供了模板。